Although there are conflicting results from cardioprotective trials, strategies have shown that the use of cardioprotective drugs such as ACE inhibitors, angiotensin receptor blockers, beta-blockers, or statins can effectively reduce the risk of cardiotoxicity in cancer patients [38,39]. The gene discussed is ACE; the disease is cancer.